PDS Biotechnology Corporation (PDSB) stock soared 5.82% in the after-hours trading session at the price of $14.55 after it appointed Matthew Hill as its Chief Financial Officer. PDSB is a clinical-stage immunotherapy company. It develops and commercializes cancer immunotherapies based on its Versamune T-cell activating technology.
PDSB Appointed Matthew Hill as Chief Financial Officer
On 6th October 2021, PDSB announced it appointed Matthew Hill as its Chief Financial Officer (CFO). The appointment became effective from 18th October 2021. Mr. Hill succeeded Seth Van Voorhees and will manage PDSB’s financial strategy for the next chapter of growth.
Mr. Hill brings 25 years of financial and operational leadership experience to PDS Biotechnology. During his last several years, he has served at Strata Skin Sciences as the Chief Financial Officer. Before joining SSKN, he held CFO roles at various companies, including EP Medsystems, where he had worked as the VP of Operations. Mr. Hill did his bachelor’s in accounting from Lehigh University.
Management Comments
CEO of PDSB, Dr. Frank Bedu-Addo, commented that their primary focus is the development of novel and efficient cancer treatments. Mr. Matt’s vast experience with healthcare and life science companies will provide solid financial leadership to PDSB. He looks forward to working closely with Matt to meet the promise of bringing novel oncology products to the market. He thanked Seth for his services to the company and wished him good luck for his future efforts.
Mr. Matthew Hill remarked, he was delighted to join PDSB. The company has accomplished notable milestones in a couple of years. He is excited to present his experience and leadership to direct PDSB’s financial strategy to expedite its growth.
First Stage Enrollment of VERSATILE-002 Phase-II Study
On 4th October 2021, PDSB reported that it had completed enrollment for the first stage of the CPI naïve arm of phase 2 clinical trial of its VERSATILE-002. It treats chronic and metastatic human papillomavirus (HPV16)-related head and neck cancer. The study published in the Journal of Clinical Medicine revealed that 90% of HPV-associated head and neck cancers has caused by HPV16.
VERSATILE-002 has analyzed two groups of HPV16-positive head and neck cancer patients whose cancer has either recurred or spread. The first group has not previously been treated with a checkpoint inhibitor. The second group of patients has failed various therapies, including checkpoint inhibitor therapy. After achieving objective responses from at least four of the 17 patients, PDSB will advance towards the second stage of the clinical trial.
